Literature DB >> 35920621

Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases.

Yanxia Bi1,2, Jian Su3,4, Shengru Zhou5, Yingjie Zhao1,2, Yan Zhang1,2, Huihui Zhang1,2, Mingdong Liu1,2, Aiwu Zhou2, Jianrong Xu2, Meng Pan5, Yiming Zhao3,4, Fubin Li1,2.   

Abstract

IgG4 is the least potent human IgG subclass for the FcγR-mediated antibody effector function. Paradoxically, IgG4 is also the dominant IgG subclass of pathogenic autoantibodies in IgG4-mediated diseases. Here, we show that the IgG subclass and Fc-FcγR interaction have a distinct impact on the pathogenic function of autoantibodies in different IgG4-mediated diseases in mouse models. While IgG4 and its weak Fc-FcγR interaction have an ameliorative role in the pathogenicity of anti-ADAMTS13 autoantibodies isolated from thrombotic thrombocytopenic purpura (TTP) patients, they have an unexpected exacerbating effect on anti-Dsg1 autoantibody pathogenicity in pemphigus foliaceus (PF) models. Strikingly, a non-pathogenic anti-Dsg1 antibody variant optimized for FcγR-mediated effector function can attenuate the skin lesions induced by pathogenic anti-Dsg1 antibodies by promoting the clearance of dead keratinocytes. These studies suggest that IgG effector function contributes to the clearance of autoantibody-Ag complexes, which is harmful in TTP, but beneficial in PF and may provide new therapeutic opportunity.
© 2022, Bi et al.

Entities:  

Keywords:  ADAMTS13; Fc-FcγR interaction; IgG4; autoantibody; desmoglein 1; human; immunology; inflammation; mouse

Mesh:

Substances:

Year:  2022        PMID: 35920621      PMCID: PMC9385207          DOI: 10.7554/eLife.76223

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.713


  60 in total

Review 1.  Clearance of apoptotic cells in human SLE.

Authors:  U S Gaipl; A Kuhn; A Sheriff; L E Munoz; S Franz; R E Voll; J R Kalden; M Herrmann
Journal:  Curr Dir Autoimmun       Date:  2006

2.  Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2013-11-15       Impact factor: 9.941

Review 3.  Diversification of IgG effector functions.

Authors:  Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Int Immunol       Date:  2017-07-01       Impact factor: 4.823

4.  Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis.

Authors:  R Clynes; C Dumitru; J V Ravetch
Journal:  Science       Date:  1998-02-13       Impact factor: 47.728

5.  Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions.

Authors:  Shengru Zhou; Zhicui Liu; Huijie Yuan; Xiaoqing Zhao; Yaru Zou; Jie Zheng; Meng Pan
Journal:  J Invest Dermatol       Date:  2019-08-31       Impact factor: 8.551

6.  Restoration of tolerance in lupus by targeted inhibitory receptor expression.

Authors:  Tracy L McGaha; Brian Sorrentino; Jeffrey V Ravetch
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

7.  Fc receptors are required in passive and active immunity to melanoma.

Authors:  R Clynes; Y Takechi; Y Moroi; A Houghton; J V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

8.  Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.

Authors:  M G Mahoney; Z H Wang; J R Stanley
Journal:  J Invest Dermatol       Date:  1999-07       Impact factor: 8.551

Review 9.  Influence of immunoglobulin isotype on therapeutic antibody function.

Authors:  Stephen A Beers; Martin J Glennie; Ann L White
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

Review 10.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.